Quinolin(on)es and pyridin(on)es as promising scaffolds against mycobacterial infections
Abstract
Mycobacterial infections pose a significant global health challenge. In 2024, 1.23 million deaths were associated with M. tuberculosis (M.tb). In recent years, the number of recorded cases of non-tuberculous mycobacterial infections has risen, particularly among elderly patients or people with underlying pulmonary diseases. Due to the emergence of antibioresistance, the discovery of new drugs which target essential enzymes in mycobacteria is required to move towards new therapeutic options for future years. Some current clinical drugs contain promising scaffolds, which serve as a basis for other researches in medicinal chemistry. The increasing interest of quinoline, quinolone, pyridine and pyridone cores is driven by their promising biological effects, initially as antibacterial agents, and more specifically, as antimycobacterial agents. The drug discovery strategy focuses on three main biological targets: the mycolic acids biosynthesis, the mycobacterial energy metabolism and DNA metabolism. Hence, this review aims to highlight the development of novel antimycobacterial agents, based on these four promising scaffolds by presenting the design strategy and biological results of recent studies.
Related
- Exploring the next “phage” of treating non-tuberculous mycobacterial infections
- Shared and distinct immunometabolic states link to divergent pathology in cutaneous mycobacterial infections
- Targeted next-generation sequencing: a promising approach for pathogen and antimicrobial resistance gene detection in urinary tract infections
- In-silico Exploration of Drug Leads Targeting Mycobacterial Ag85C
- Engineered probiotics target granulomas to treat mycobacterial infection
BibTeX
@article{greverie2026quinolinones,
title = {{Quinolin(on)es and pyridin(on)es as promising scaffolds against mycobacterial infections}},
author = {Marie Gréverie and Alexandra Dassonville-Klimpt and Morgane Choquet and Claire Andréjak and Pascal Sonnet},
journal = {Bioorganic and Medicinal Chemistry Letters},
year = {2026},
month = sep,
doi = {10.1016/j.bmcl.2026.130781},
url = {https://u-picardie.hal.science/hal-05753395v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Quinolin(on)es and pyridin(on)es as promising scaffolds against mycobacterial infections
AU - Marie Gréverie
AU - Alexandra Dassonville-Klimpt
AU - Morgane Choquet
AU - Claire Andréjak
AU - Pascal Sonnet
PY - 2026
DA - 2026/09/16
JO - Bioorganic and Medicinal Chemistry Letters
DO - 10.1016/j.bmcl.2026.130781
UR - https://u-picardie.hal.science/hal-05753395v1
AB - Mycobacterial infections pose a significant global health challenge. In 2024, 1.23 million deaths were associated with M. tuberculosis (M.tb). In recent years, the number of recorded cases of non-tuberculous mycobacterial infections has risen, particularly among elderly patients or people with underlying pulmonary diseases. Due to the emergence of antibioresistance, the discovery of new drugs which target essential enzymes in mycobacteria is required to move towards new therapeutic options for future years. Some current clinical drugs contain promising scaffolds, which serve as a basis for other researches in medicinal chemistry. The increasing interest of quinoline, quinolone, pyridine and pyridone cores is driven by their promising biological effects, initially as antibacterial agents, and more specifically, as antimycobacterial agents. The drug discovery strategy focuses on three main biological targets: the mycolic acids biosynthesis, the mycobacterial energy metabolism and DNA metabolism. Hence, this review aims to highlight the development of novel antimycobacterial agents, based on these four promising scaffolds by presenting the design strategy and biological results of recent studies.
SN - 0960-894X
ER -